All Eyes on Previously Overlooked Pharma and Biotech... Will Optimism Last Through Year-End?

The pharmaceutical and biotech sectors, which had been overlooked during the semiconductor-led market rally, have recently shown strong performance. The healthcare index has significantly outperformed the semiconductor index, attracting strong foreign buying. Easing U.S. tariff risks and news of global new drug and technology transfers are boosting domestic investor sentiment.

Securities firms predict that this trend will continue through the first half of next year. Global trends such as obesity and metabolic disease treatments, along with domestic companies' technology exports and new drug approval achievements, are having a positive impact, indicating ample room for further gains. Experts advise, "It is effective to develop a bio investment strategy alongside semiconductors and high-dividend stocks in line with the rotational market expected through the end of the year."

[Go to the No.1 HiStockLoan in the industry: https://www.hisl.co.kr/5113]

Meanwhile, interest in stock loans continues to rise. Investors seeking to seize rare investment opportunities are turning to stock loans, which allow them to utilize more funds for stock purchases.

Another advantage of stock loans is that even if investors face a forced sale crisis due to a sharp stock price drop while using margin or credit, they can simply switch products without providing additional collateral or selling stocks and wait for a rebound.

◆ HiStockLoan: Industry’s lowest annual interest rate in the 4% range, offering not only additional investment funds but also credit refinancing!

HiStockLoan has launched a securities-linked credit product with an industry-low interest rate in the 4% range, allowing anyone to experience stock loans without burden. It can be used for stock purchases as well as refinancing margin/credit from securities firms, and up to four times the investor’s own capital can be utilized regardless of credit rating.

In addition, for investors who have had difficulty using existing stock loans due to DSR limits, products are available that can be used regardless of DSR. Investors using the alternative trading system (NXT) can also take advantage of these offerings.

Investors who wish to learn more about HiStockLoan’s various customized products can contact the customer service center (☎1566-5113) for convenient consultation with a professional advisor 24 hours a day, regardless of loan approval.

○ Launch of industry’s lowest annual interest rate products in the 4% range

○ Products available regardless of DSR

○ No.1 market share for 21 consecutive years, Korea First Brand Award for 16 consecutive years

○ Real-time repayment of margin/credit from securities firms

○ Available for alternative trading system (NXT) transactions

○ Reliable consultation quality guarantee system

* HiStockLoan Consultation Center: 1566-5113

Direct link: https://www.hisl.co.kr/5113

Green Optics, Alt, Rokit Healthcare, ImmuneOncia, Pharmicell

※ The content above is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.

This content was produced with the assistance of AI translation services.